Clinical trial
Safety, Tolerability and Efficacy of XTL 2125 in HCV-Infected Patients Who Are…
NCT00255359 · Hadassah Medical Organization, Other · Withdrawn
Key facts
| NCT number | NCT00255359 |
|---|---|
| Title | Safety, Tolerability and Efficacy of XTL 2125 in HCV-Infected Patients Who Are Interferon-Alpha Non-Responders or Relapsers |
| Official title | A Multicenter, Randomized, Double-Blind, Placebo Controlled, Dose Escalation Study of the Safety and Efficacy of XTL 2125 in Adult HCV-Infected Patients With Compensated Liver Disease, Who Are Interferon-Alpha Non-Responders or Have Relapsed From Interferon-Alpha Therapy |
| Lead sponsor | Hadassah Medical Organization, Other |
| Collaborators | XTL Biopharmaceuticals Industry |
| Status | Withdrawn |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Chronic Hepatitis C Virus Infection |
| Intervention type | Drug |
| Interventions | XTL-2125 |
| Enrollment | 60 |
| Start date | Feb 1, 2006 |
| Completion | Nov 1, 2007 |
| First posted | Nov 18, 2005 |
| Last update posted | Nov 6, 2007 |
| Countries | Israel |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: